NCT06381583View on ClinicalTrials.gov

A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma

CompletedOBSERVATIONAL
Enrollment

658

Participants

Timeline

Start Date

April 15, 2023

Primary Completion Date

April 24, 2024

Study Completion Date

April 24, 2024

Conditions
Esophagus CancerEsophageal Cancer StageEsophageal CancerEsophageal NeoplasmsEsophagus AdenocarcinomaEsophagus, BarrettBarrett EsophagusBarrett AdenocarcinomaBarrett EpitheliumBarretts Esophagus With DysplasiaBarrett's Esophagus Without DysplasiaBarretts Esophagus With High Grade DysplasiaBarretts Esophagus With Low Grade DysplasiaBarrett Esophagus, Long-SegmentBarrett's Esophagus With Dysplasia, UnspecifiedBarrett's Esophagus With EsophagitisGastroesophageal RefluxReflux DiseaseEsophageal AdenocarcinomaEsophageal DysplasiaEsophageal Neoplasms Malignant
Interventions
DIAGNOSTIC_TEST

EMERALD (Esophageal MicroRNAs for BaRRett's esophagus, Adenocarcinoma, and Dysplasia)

A panel of circulating microRNA, whose expression level is tested in cell-free derived samples.

Trial Locations (1)

91016

City of Hope Medical Center, Duarte

All Listed Sponsors
lead

City of Hope Medical Center

OTHER